Statins in acute coronary syndrome: Very early initiation and benefits

Therapeutic Advances in Cardiovascular Disease

Volumn 6, Issue 4, 2012, Pages 163-174

  Angeli, Fabio ^a   Reboldi, Gianpaolo ^b   Mazzotta, Giovanni ^c   Garofoli, Marta ^c   Cerasa, Maria Francesca ^c   Verdecchia, Paolo ^c  

^a Hospital Media Valle Del Tevere   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Hospital of Assisi   (Italy)

Author keywords

acute coronary syndrome; HMG CoA reductase inhibitors; percutaneous coronary intervention; prognosis; treatment

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CARDIOVASCULAR MORTALITY; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG MECHANISM; DRUG MEGADOSE; FAMILY HISTORY; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; INTRAVASCULAR ULTRASOUND; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; ST SEGMENT ELEVATION; STENT THROMBOSIS; TREATMENT DURATION;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; C-REACTIVE PROTEIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS;

EID: 84865097559     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944712452463     Document Type: Review

References (51)

1. Angeli F. Reboldi G. Garofoli M. Ramundo E. Verdecchia P. (2012) Very early initiation of statin therapy and mortality in patients with acute coronary syndrome. Acute Card Care 14: 34–39.
2. Aronow H. Topol E. Roe M. Houghtaling P. Wolski K. Lincoff A. et al. (2001) Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 357: 1063–1068.
3. Bavry A. Mood G. Kumbhani D. Borek P. Askari A. Bhatt D. (2007) Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: a systematic review of randomized trials. Am J Cardiovasc Drugs 7: 135–141.
4. Briel M. Vale N. Schwartz G. de Lemos J. Colivicchi F. Den Hartog F. et al. (2011) Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients. Int J Cardiol, in press.
5. Briguori C. Colombo A. Airoldi F. Violante A. Focaccio A. Balestrieri P. et al. (2004) Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J 25: 1822–1828.
6. Bustos C. Hernandez-Presa M. Ortego M. Tunon J. Ortega L. Perez F. et al. (1998) HMG-COA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32: 2057–2064.
7. Cannon C. Braunwald E. McCabe C. Rader D. Rouleau J. Belder R. et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495–1504.
8. Cannon C. Steinberg B. Murphy S. Mega J. Braunwald E. (2006) Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48: 438–445.
9. Chan A. Bhatt D. Chew D. Quinn M. Moliterno D. Topol E. et al. (2002) Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 105: 691–696.
10. de Lemos J. Blazing M. Wiviott S. Lewis E. Fox K. White H. et al. (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292: 1307–1316.
11. Den Hartog F. van Kalmthout P. van Loenhout T. Schaafsma H. Rila H. Verheugt F. (2001) Pravastatin in acute ischaemic syndromes: results of a randomised placebo-controlled trial. Int J Clin Pract 55: 300–304.
12. Fukumoto Y. Libby P. Rabkin E. Hill C. Enomoto M. Hirouchi Y. et al. (2001) Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 103: 993–999.
13. Granger C. Weaver W. (2004) Reducing cardiac events after acute coronary syndromes. Rev Cardiovasc Med 5(Suppl. 5): S39–S46.
14. Gregoire G. Derderian F. Le Lorier J. (1995) Selecting the language of the publications included in a meta-analysis: is there a tower of Babel bias? J Clin Epidemiol 48: 159–163.
15. Haynes R. Wilczynski N. McKibbon K. Walker C. Sinclair J. (1994) Developing optimal search strategies for detecting clinically sound studies in Medline. J Am Med Inform Assoc 1: 447–458.
16. Heeschen C. Hamm C. Laufs U. Snapinn S. Bohm M. White H. (2002) Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 105: 1446–1452.
17. Johnson J. Carson K. Williams H. Karanam S. Newby A. Angelini G. et al. (2005) Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation 111: 1422–1430.
18. Kawasaki M. Sano K. Okubo M. Yokoyama H. Ito Y. Murata I. et al. (2005) Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol 45: 1946–1953.
19. Kayikcioglu M. Can L. Kultursay H. Payzin S. Turkoglu C. (2002) Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty. Acta Cardiol 57: 295–302.
20. Kesteloot H. Claeys G. Blanckaert N. Lesaffre E. (1997) Time course of serum lipids and apolipoproteins after acute myocardial infarction: modification by pravastatin. Acta Cardiol 52: 107–116.
21. Lenderink T. Boersma E. Gitt A. Zeymer U. Wallentin L. van de Werf F. et al. (2006) Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the First Euro Heart Survey on Acute Coronary Syndromes. Eur Heart J 27: 1799–1804.
22. Liao J. (2005) Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96: 24F–33F.
23. Liem A. van Boven A. Veeger N. Withagen A. Robles de Medina R. Tijssen J. et al. (2002) Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 23: 1931–1937.
24. Macin S. Perna E. Farias E. Franciosi V. Cialzeta J. Brizuela M. et al. (2005) Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. Am Heart J 149: 451–457.
25. Mcauley L. Pham B. Tugwell P. Moher D. (2000) Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet 356: 1228–1231.
26. Mihos C. Salas M. Santana O. (2010) The pleiotropic effects of the hydroxy-methyl-glutaryl-COA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev 18: 298–304.
27. Moustapha A. Anderson H. (2003) Contemporary view of the acute coronary syndromes. J Invasive Cardiol 15: 71–79.
28. Newby L. Kristinsson A. Bhapkar M. Aylward P. Dimas A. Klein W. et al. (2002) Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 287: 3087–3095.
29. Okazaki S. Yokoyama T. Miyauchi K. Shimada K. Kurata T. Sato H. et al. (2004) Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the Establish Study. Circulation 110: 1061–1068.
30. Ostadal P. Alan D. Vejvoda J. Kukacka J. Macek M. Hajek P. et al. (2010) Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double- blind, placebo-controlled trial (the FACS-Trial). Trials 11: 61.
31. Otsuka F. Hibi K. Kusama I. Endo M. Kosuge M. Iwahashi N. et al. (2010) Impact of statin pretreatment on the incidence of plaque rupture in ST-elevation acute myocardial infarction. Atherosclerosis 213: 505–511.
32. Paradiso-Hardy F. Gordon W. Jackevicius C. Kertland H. Pearson G. Pickering J. et al. (2003) The importance of in-hospital statin therapy for patients with acute coronary syndromes. Pharmacotherapy 23: 506–513.
33. Pasceri V. Patti G. Nusca A. Pristipino C. Richichi G. Di Sciascio G. (2004) Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Study. Circulation 110: 674–678.
34. Pedersen T. Faergeman O. Kastelein J. Olsson A. Tikkanen M. Holme I. et al. (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the Ideal Study: a randomized controlled trial. JAMA 294: 2437–2445.
35. Pepine C. (2003) Optimizing lipid management in patients with acute coronary syndromes. Am J Cardiol 91: 30B–35B.
36. Ray K. Cannon C. McCabe C. Cairns R. Tonkin A. Sacks F. et al. (2005) Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the Prove It-Timi 22 Trial. J Am Coll Cardiol 46: 1405–1410.
37. Ren H. Ma L. Wang L. (2009) Effect of simvastatin on plasma interleukin-6 in patients with unstable angina. Clin Invest Med 32: E280–E284.
38. Roger V. Go A. Lloyd-Jones D. Benjamin E. Berry J. Borden W. et al. (2012) Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 125: e2–e220.
39. Schartl M. Bocksch W. Koschyk D. Voelker W. Karsch K. Kreuzer J. et al. (2001) Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104: 387–392.
40. Schwartz G. Olsson A. Ezekowitz M. Ganz P. Oliver M. Waters D. et al. (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL Study: a randomized controlled trial. JAMA 285: 1711–1718.
41. Serruys P. de Feyter P. Macaya C. Kokott N. Puel J. Vrolix M. et al. (2002) Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287: 3215–3222.
42. Serruys P. Foley D. Jackson G. Bonnier H. Macaya C. Vrolix M. et al. (1999) A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the Fluvastatin Angiographic Restenosis (Flare) Trial. Eur Heart J 20: 58–69.
43. Spencer F. Allegrone J. Goldberg R. Gore J. Fox K. Granger C. et al. (2004) Association of statin therapy with outcomes of acute coronary syndromes: The Grace Study. Ann Intern Med 140: 857–866.
44. Takano M. Mizuno K. Yokoyama S. Seimiya K. Ishibashi F. Okamatsu K. et al. (2003) Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy. J Am Coll Cardiol 42: 680–686.
45. Takarada S. Imanishi T. Kubo T. Tanimoto T. Kitabata H. Nakamura N. et al. (2009) Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. Atherosclerosis 202: 491–497.
46. Thompson P. Meredith I. Amerena J. Campbell T. Sloman J. Harris P. (2004) Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) Trial. Am Heart J 148: e2.
47. Walter D. Fichtlscherer S. Britten M. Rosin P. Auch-Schwelk W. Schachinger V. et al. (2001) Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 38: 2006–2012.
48. Waters D. Hsue P. (2001) What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes? Am J Cardiol 88: 7J–16J.
49. Wiviott S. Cannon C. Morrow D. Ray K. Pfeffer M. Braunwald E. (2005) Can low-density lipoprotein be too low? the safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a Prove It-Timi 22 Substudy. J Am Coll Cardiol 46: 1411–1416.
50. Wright R. Anderson J. Adams C. Bridges C. Casey D. Ettinger S. et al. (2011) 2011 ACCF / AHA focused update incorporated into the ACC / AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 57: e215–e367.
51. Zhu S. Viswambharan H. Gajanayake T. Ming X. Yang Z. (2005) Sirolimus increases tissue factor expression but not activity in cultured human vascular smooth muscle cells. BMC Cardiovasc Disord 5: 22.